199 related articles for article (PubMed ID: 25401269)
1. Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome.
Cai QQ; Wang C; Cao XX; Cai H; Zhou DB; Li J
Eur J Haematol; 2015 Oct; 95(4):325-30. PubMed ID: 25401269
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation.
Vannata B; Laurenti L; Chiusolo P; Sorà F; Balducci M; Sabatelli M; Luigetti M; Giannotta C; De Stefano V; Leone G; Sica S
Am J Hematol; 2012 Jun; 87(6):641-2. PubMed ID: 22488443
[TBL] [Abstract][Full Text] [Related]
3. A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome.
Li J; Huang XF; Cai QQ; Wang C; Cai H; Zhao H; Zhang L; Cao XX; Gale RP; Zhou DB
Am J Hematol; 2018 Jun; 93(6):803-809. PubMed ID: 29603764
[TBL] [Abstract][Full Text] [Related]
4. [The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis].
Adam Z; Pour L; Krejčí M; Zahradová L; Szturz P; Koukalová R; Rehák Z; Nebeský T; Hájek R; Král Z; Mayer J
Vnitr Lek; 2012 Nov; 58(11):856-66. PubMed ID: 23256832
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide Treatment for Thalidomide-refractory POEMS Syndrome: A Prospective Single-arm Clinical Trial.
Suichi T; Misawa S; Nagashima K; Sato Y; Iwai Y; Katayama K; Sekiguchi Y; Shibuya K; Amino H; Suzuki YI; Tsuneyama A; Nakamura K; Kuwabara S
Intern Med; 2020 May; 59(9):1149-1153. PubMed ID: 32009091
[TBL] [Abstract][Full Text] [Related]
6. [POEMS syndrome treated with lenalidomide plus high-dose dexamethasone as a pre-transplant induction therapy].
Matsuura S; Ogusa E; Taguchi J; Imai N; Fujita H; Tomita N; Ishigatsubo Y; Fujisawa S
Rinsho Ketsueki; 2012 Dec; 53(12):2025-8. PubMed ID: 23318971
[TBL] [Abstract][Full Text] [Related]
7. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Jakubowiak AJ; Richardson PG; Zimmerman T; Alsina M; Kaufman JL; Kandarpa M; Kraftson S; Ross CW; Harvey C; Hideshima T; Sportelli P; Poradosu E; Gardner L; Giusti K; Anderson KC
Br J Haematol; 2012 Aug; 158(4):472-80. PubMed ID: 22640031
[TBL] [Abstract][Full Text] [Related]
8. [Rapid improvement of fluid retention with lenalidomide plus low-dose dexamethasone for POEMS syndrome relapsed after autologous peripheral blood stem cell transplantation].
Ohashi K; Yokoyama A; Kagoo T; Hosoda T; Yamamoto R; Yoneda M; Kudo M; Boku S; Ueno H; Yano T
Rinsho Ketsueki; 2013 Jul; 54(7):670-4. PubMed ID: 23912352
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of POEMS syndrome with lenalidomide and dexamethasone].
Goto A; Iyama S; Sugama Y; Yoshida M; Ibata S; Tatekoshi A; Fujita C; Kikuchi S; Ikeda H; Murase K; Takada K; Kato J; Kobune M
Rinsho Ketsueki; 2019; 60(4):308-313. PubMed ID: 31068561
[TBL] [Abstract][Full Text] [Related]
12. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
Tufail M; Siegel DS; McBride L; Bilotti E; Bello E; Anand P; Olivo K; Bendarz U; McNeill A; Vesole DH
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):186-90. PubMed ID: 22381702
[TBL] [Abstract][Full Text] [Related]
14. What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone?
Zhao H; Huang XF; Gao XM; Cai H; Zhang L; Feng J; Cao XX; Zhou DB; Li J
Leukemia; 2019 Apr; 33(4):1023-1029. PubMed ID: 30700844
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients.
Royer B; Merlusca L; Abraham J; Musset L; Haroche J; Choquet S; Leleu X; Sebban C; Decaux O; Galicier L; Roussel M; Recher C; Banos A; Guichard I; Brisseau JM; Godmer P; Hermine O; Deplanque G; Facon T; Asli B; Leblond V; Fermand JP; Marolleau JP; Jaccard A
Am J Hematol; 2013 Mar; 88(3):207-12. PubMed ID: 23335406
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
[TBL] [Abstract][Full Text] [Related]
17. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial.
Nozza A; Terenghi F; Gallia F; Adami F; Briani C; Merlini G; Giordano L; Santoro A; Nobile-Orazio E
Br J Haematol; 2017 Dec; 179(5):748-755. PubMed ID: 29048107
[TBL] [Abstract][Full Text] [Related]
19. "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
Katodritou E; Vadikolia C; Lalagianni C; Kotsopoulou M; Papageorgiou G; Kyrtsonis MC; Matsouka P; Giannakoulas N; Kyriakou D; Karras G; Anagnostopoulos N; Michali E; Briasoulis E; Hatzimichael E; Spanoudakis E; Zikos P; Tsakiridou A; Tsionos K; Anargyrou K; Symeonidis A; Maniatis A; Terpos E
Ann Hematol; 2014 Jan; 93(1):129-39. PubMed ID: 23892921
[TBL] [Abstract][Full Text] [Related]
20. Improvement of sexual function in POEMS syndrome after combination therapy of Lenalidomide and dexamethasone.
Yang H; Huang X; Cai Q; Wang C; Cao X; Zhou D; Li J
Orphanet J Rare Dis; 2016 Jun; 11(1):80. PubMed ID: 27317315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
